Conference Coverage

Post Hoc Analysis Examines Health Status and Quality of Life With Acoramidis in p.Val142Ile ATTRv-CM

Edited by:
Brian McCurdy

Key Highlights

  • The analysis included 35 participants with p.Val142Ile variant transthyretin amyloid cardiomyopathy, including 23 receiving acoramidis and 12 receiving placebo.
  • Those receiving acoramidis showed significantly attenuated deterioration in KCCQ-OS and 2 health-related quality-of-life measures through 30 months.
  • The between-group difference in 6-minute walk distance favored acoramidis but did not reach statistical significance.
  • Findings came from a post hoc subgroup analysis of the randomized ATTRibute-CM trial.

In a poster presented at the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting, acoramidis significantly attenuated declines in heart failure-related health status and health-related quality of life over 30 months compared with placebo in patients with p.Val142Ile variant transthyretin amyloid cardiomyopathy (ATTRv-CM). The post hoc ATTRibute-CM analysis also found a numerically smaller decline in functional capacity, although that difference was not statistically significant.

The investigators described p.Val142Ile as the most common transthyretin variant worldwide and one associated with worse heart failure-related health status and quality of life than other variants. They sought to characterize acoramidis treatment effects on these outcomes, alongside functional capacity, in this subgroup.

ATTRibute-CM focused on participants with p.Val142Ile in the modified intention-to-treat population, comprising 23 assigned to acoramidis and 12 assigned to placebo. Investigators assessed changes from baseline in 6-minute walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score, EQ-5D-5L index, and EQ visual analog scale (VAS) score. They used mixed effects models for repeated measures to evaluate outcomes through month 30.

Study Findings

The researchers found that acoramidis was associated with a numerically smaller decline in 6MWD than placebo, with a least-squares mean between-group difference of 67.2 m (95% CI, −21.0 to 155.4; P = .136). The treatment significantly attenuated decline in KCCQ-OS score, with a difference of 23.3 points favoring acoramidis (95% CI, 7.1–39.4; P = .005).

Both health-related quality-of-life measures also favored acoramidis. The between-group difference was 0.26 for the EQ-5D-5L index (95% CI, 0.05–0.47; P = .018) and 25.8 points for the EQ VAS (95% CI, 8.8–42.9; P = .003).

Clinical Implications

According to the investigators, the findings complement previously reported survival benefits of acoramidis in this high-risk population. They identified preservation of functional capacity, health status, and quality of life as therapeutic goals alongside improved survival in patients with p.Val142Ile ATTRv-CM.

The authors concluded that health status and quality-of-life deterioration were significantly attenuated, with a trend toward less functional decline.

Reference

Stern LK, Akinboboye O, Davis MK, et al. Acoramidis preserves functional capacity and quality of life in p.Val142Ile variant transthyretin amyloid cardiomyopathy: results from ATTRibute-CM. HFSA ePoster Library. October 11, 2026. Abstract 605. ePoster 4235243.